Stryker Neurovascular announced today that its Trevo® Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo® Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever® Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.
The Trevo® Pro Retriever demonstrated strong clinical results in the TREVO 2 clinical trial presented at the 2012 European Stroke Conference in May. This technology demonstrated the highest rate of revascularization in a randomized embolectomy stroke device trial, and achieved significantly better post-procedure revascularization than the Merci Retriever® (92% in the Trevo® Retriever arm compared to 76.7% in the Merci Retriever® arm). Other measures of performance also strongly favored the Trevo® Pro Retriever, including improvement in the National Institutes of Health Stroke Scale (NIHSS) score, excellent composite safety endpoints and shorter hospital stays.
"The launch of this device is another great stride in the evolution of stroke care," said TREVO 2 Investigator Gary Duckwiler, MD at University of California Los Angeles Medical Center. "Concentric Medical, which is now owned by Stryker, has a long history of partnering with physicians to develop devices specifically designed to remove blood clots from a blocked artery in the brain. The new Trevo® Pro Retriever is easy to use and very effective at opening blood vessels; allowing physicians to have a significant impact on clinical outcomes."